Biotech catalysts: upcoming clinical trial readouts and FDA dates
Upcoming clinical trial readouts, PDUFA target dates, FDA advisory committee meetings, marketing applications, FDA designations and clinical holds for US-listed biotech and pharma companies, each with the date the company gave, the drug, the trial phase and a link to the disclosure it was read from.
Biotech catalyst events disclosed by US-listed companies
Source: company press releases and SEC filings (8-K, 6-K), compiled by Signal8.
124 upcoming catalysts in this window. Dates are as the company disclosed them; a ~ marks a date given only as a quarter, a half year or a month. A dash means not measured. Not investment advice.
About this list
Every event comes from a company’s own press release or SEC filing, mostly a Form 8-K. Signal8 reads each disclosure, records the event type, the drug and the date, and keeps the newest version when a company moves a date. A date a company gave only as a quarter, a half year or a month is shown as that period, not as a day.
An event on this page records that a company disclosed a date. It does not say what a trial will show or what the FDA will decide, and the FDA can act before a PDUFA date, after it, or announce nothing on the day.
Frequently asked questions
What is a biotech catalyst?
A dated event that new information about a drug comes out of: clinical trial results, an FDA action on a PDUFA date, an advisory committee meeting, a marketing application, an FDA designation or a clinical hold. This page lists the ones US-listed companies have disclosed.
What is a PDUFA date?
The target date for the FDA to act on a new drug application (NDA) or biologics license application (BLA), set under the Prescription Drug User Fee Act. For a new molecular entity the goal is 10 months after the 60-day filing date under standard review and 6 months under priority review. The company discloses the date; the FDA does not publish it.
What is a clinical trial readout?
The release of results from a clinical trial. Topline data is the first summary of the main endpoints, an interim readout looks at the data before the trial ends, and final data covers the completed trial. Companies often give a quarter or a half year for a readout rather than a date.
What do Phase 1, Phase 2 and Phase 3 mean?
Phase 1 is the first test of a drug in people, in a small group, mainly for safety and dose. Phase 2 tests it in a larger group of patients for effect and further safety. Phase 3 compares it with placebo or the standard treatment in a large group, and its results are usually the main evidence in a marketing application.
What is an FDA advisory committee (AdCom) meeting?
A public meeting where outside experts discuss an application and vote on questions the FDA puts to them. The FDA is not bound by the vote. The agency announces each meeting in the Federal Register.
Where do the dates come from?
From the companies’ own press releases and SEC filings, linked from each row as Source. Signal8 does not estimate a date a company has not given. When a company moves a date, the newer disclosure replaces the older one.
Why does a row show a quarter instead of a date?
Because the company gave only a quarter, a half year or a month. The countdown for such a row counts to the end of that period, is marked with a ~ and is approximate.
Does the page show past results?
Yes. The History tab lists catalysts from about the last 90 days with the outcome on record: an FDA approval or complete response letter, or whether a readout met its primary endpoint as the company reported it. A row with no outcome on record says Pending, or shows a dash where the event type has no outcome.
Does a catalyst say how the stock will move?
No. A catalyst records that a company disclosed an event and its date. It does not say what the result will be or how the share price will respond.